Skip to main content
Michael Rippee, MD, Neurology, Kansas City, KS, The University of Kansas Hospital

MichaelA.JamesRippeeMD

Neurology Kansas City, KS

Sports Neurologist, Concussion expert, Medical Director for the Center for Concussion Management at The University of Kansas Health System Associate Professor, Neurology, University Kansas School of Medicine

Dr. Rippee is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Rippee's full profile

Already have an account?

Education & Training

  • University of Kansas School of Medicine
    University of Kansas School of MedicineFellowship, Vascular Neurology, 2011 - 2012
  • University of Kansas School of Medicine
    University of Kansas School of MedicineResidency, Neurology, 2008 - 2011
  • University of Missouri Kansas City School of Medicine
    University of Missouri Kansas City School of MedicineClass of 2007

Certifications & Licensure

  • KS State Medical License
    KS State Medical License 2011 - 2024
  • American Board of Psychiatry and Neurology Neurology
  • American Board of Psychiatry and Neurology Vascular Neurology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Oxeia Announces Positive Interim Results of Phase 2 Trial for oxe103 for the Treatment of Concussions
    Oxeia Announces Positive Interim Results of Phase 2 Trial for oxe103 for the Treatment of ConcussionsAugust 3rd, 2022
  • Symptoms You May Experience After Getting a COVID-19 Vaccine
    Symptoms You May Experience After Getting a COVID-19 VaccineJanuary 5th, 2021
  • Oxeia Biopharmaceuticals, Inc. Announces Initiation of Phase 2 Trial for OXE103 for the Treatment of Concussions
    Oxeia Biopharmaceuticals, Inc. Announces Initiation of Phase 2 Trial for OXE103 for the Treatment of ConcussionsOctober 21st, 2020
  • Join now to see all

Hospital Affiliations